

**INVESTOR PRESENTATION TO SHARECAFÉ SMALL CAPS WEBINAR***Friday 10 September 2021, 12.30pm (AEDT)*

**Adelaide, Australia, 9 September 2021:** Australian hi-tech company Micro-X Ltd (ASX:MX1) (**Micro-X** or the **Company**), a leader in cold cathode x-ray technology for health and security markets globally, announces that the Company's CEO and Managing Director, Peter Rowland, will be presenting at the ShareCafé Small Cap "Hidden Gems" webinar at 12.30pm on Friday 10 September 2021 (AEDT).

Micro-X CEO and Managing Director, Peter Rowland, will provide the attached presentation on the Company, followed by a question and answer session.

To register to attend this free investor event, please use the following link:

[https://us02web.zoom.us/webinar/register/5416151767246/WN\\_VIZUS1yxTfiiglcSgtg4jq](https://us02web.zoom.us/webinar/register/5416151767246/WN_VIZUS1yxTfiiglcSgtg4jq)

The Company's presentation for the conference is attached.

This ASX Announcement is approved by Kingsley Hall, Company Secretary of Micro-X.

– ENDS –

**About Micro-X**

Micro-X Limited (the **Company**) is an ASX listed hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube (CNT) emitter technology. The electronic control of emitters with this technology enables x-ray products with significant reduction in size, weight and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security and defence applications. Micro-X has a fully vertically integrated design and production facility in Adelaide, Australia. A growing technical and commercial team based in Seattle is rapidly expanding Micro-X's US business.

Micro-X's product portfolio is built in four, high margin, product lines in health and security. The first commercial mobile digital radiology products are currently sold for diagnostic imaging in global healthcare, military and veterinary applications. An X-ray Camera for security imaging of Improvised Explosive Devices is in advanced development. The US Department of Homeland Security has selected Micro-X to design a next-generation Airport Checkpoint Portal with self-service x-ray. A miniature brain CT imager for pre-hospital stroke diagnosis in ambulances, is being developed with funding from the Australian Government's Medical Research Future Fund.

For more information visit: [www.micro-x.com](http://www.micro-x.com)

**CONTACTS**

Micro-X Limited	Investor Enquiries
<b>Peter Rowland</b> Managing Director Tel: +61 8 7099 3966 E: <a href="mailto:admin@micro-x.com">admin@micro-x.com</a>	<b>David Allen / John Granger</b> Hawkesbury Partners Tel: +61 2 9103 9494 E: <a href="mailto:dallen@hawkesburypartners.com">dallen@hawkesburypartners.com</a> <a href="mailto:jgranger@hawkesburypartners.com">jgranger@hawkesburypartners.com</a>

ACN 153 273 735 / ASX: MX1

# MICRO-X

## SHARECAFE INVESTOR WEBINAR

10th September 2021

Peter Rowland  
Managing Director & CEO



# IMPORTANT NOTICE DISCLAIMER



## SCOPE & LIMITATIONS

This Presentation has been prepared by Micro-X Limited (**Micro-X** or the **Company**) (ASX.MX1). The Presentation is a summary only and does not contain all the information about the Company's assets and liabilities, financial position and performance, profits and losses and prospects. This material in this Presentation may be supplemented with an oral presentation and/or other more detailed documents and should not be taken out of context. Although the information contained herein is based upon generally available information and has been obtained from third-party sources believed to be reliable, the Company does not guarantee its accuracy, and such information may be incomplete or condensed. The Company also refers to its filings made with the ASX Limited and the Australian Securities & Investments Commission.

## FORWARD LOOKING INFORMATION

This Presentation contains forward looking and other subjective information. Such expectations, estimates, projections and information are not a guarantee of future performance and involve unknown risks and uncertainties. Actual results and developments will almost certainly differ from those expressed or implied and recipients of this Presentation should make their own assessment of the expectations, estimates, projections and the relevant assumptions and calculations upon which the opinions, estimates and projections are based. No representation or warranty, express or implied, is given as to the accuracy or completeness of the information or opinions contained in this Presentation and no liability whatsoever is accepted by the Company, or its directors, members, officers, employees, agents or advisers for any use or, or reliance placed upon, such information or opinions.

## NOT AN OFFER FOR SECURITIES

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances.

## UNITED STATES

**The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933**, as amended (the **Securities Act**), or under the securities laws of any state or other jurisdiction of the

United States. Accordingly, the Company's securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the United States

## OTHER JURISDICTIONS

This Presentation may only be accessed in other jurisdictions where it is legal to do so.

# MINIATURISING X-RAY

First Mover in Next Generation X-ray for Global Health and Security Markets

MICRO-X

## Platform technology in cold cathode x-ray

- X-ray products with significant reduction in size, weight and power
- **Patented technology** – platform for health and new security applications
- **First to market** with proven cold cathode medical x-ray product

25kg




### Comparison

Conventional x-ray tube and Micro-X x-ray tube

1.5kg

# OUR STRATEGY

To Monetise Our 'First Mover' Advantage



## MICRO-X

### OUR GOAL

**Four global production lines**

- common technology platforms
- high-margin
- operating within five years

### OUR 4 PRODUCT LINES

#### Mobile DR

Bedside imaging – Medical, Military, Vet

#### IED X-ray Camera

Counter terrorist bomb assessment

#### Airport Checkpoint

Self-service airport security

#### Brain CT

In-ambulance stroke imaging

# MOBILE DIGITAL RADIOLOGY

Extending Bedside Imaging with Lightweight and Ultra-mobility

---

**\$3.6m**

Sales FY21

**4**

New Distributors Signed

**2021**

Rover Mark II Launched

---

## THE PRODUCT RANGE


**OEM Products** – ‘Carestream DRX-Revolution Nano’

- First sold 2018 – now operating in 20+ countries
- Other, non exclusive OEM partnerships in development

**Micro-X ‘Rover’** – wholly Micro-X branded and controlled imaging solution for:

- **Medical** hospitals & temporary facilities
- Ruggedised for deployed **military** hospitals and humanitarian aid
- **Veterinary** applications in small-animal hospitals and specialist clinics

MICRO-X





# IED X-RAY CAMERA

Next Generation Security Device to Save Lives

**\$1.8b**

Addressable market

**Prototype**

Dec 2021

**2022**


Target Launch

- ✖ X-ray camera takes images like a camera - **one sided viewing** without separate detector
- ✖ Bomb disposal technicians face life threatening situation when 'over the target' placing a conventional x-ray detector
- ✖ Small size and weight – easily carried by robots
- ✖ Australian Defence Force **proof of concept imaging completed**
- ✖ **Military and FBI / bomb disposal interest**
- ✖ **No competition = higher gross margins**

MICRO-X



Traditional x-ray of IEDs requires manual placement of separate detector



First public showing of IED X-Ray Camera at Army Robotics Conference in April 2021

# AIRPORT SELF-SERVICE CHECKPOINT

US Dept. of Homeland Security – Two Contracts Totalling US\$4m

MICRO-X

---

## US\$24b

Addressable market

## US\$4m

Two contracts for US  
Dept of Homeland  
Security

---

- ✦ A blend of backscatter and transmission x-ray to provide **three-dimensional imaging of carry on luggage**
- ✦ Integrated body scanner and passport reader
- ✦ Based on work Micro-X undertook in 2 contracts won from UK's Department for Transport
- ✦ Concept reimagines the future of airport checkpoints based on self-service model
- ✦ Addressable global market ~ US\$24B  
TSA alone US\$8B market opportunity



Above: Illustration of Future Airport Checkpoint Portal



# BRAIN CT IMAGING FOR STROKE DIAGNOSIS

Pre-Hospital Diagnosis & Treatment in Ambulance

**US\$5b**

Addressable market

**\$8m**

Australian Stroke Alliance  
– MRFF funding

PARTNERS



**FUJIFILM**



- ✘ CT imaging with no moving parts – small enough and affordable to be fitted to every ambulance
- ✘ Early stroke diagnosis allows treatment in a road or ambulance – improved patient outcomes within the ‘Golden Hour’
- ✘ Curved detector will be the first of its kind – provided in collaboration with **Fujifilm**
- ✘ **\$8m funding** under Second Phase of Australian Stroke Alliance Project – Medical Research Future Fund
- ✘ **Potential to be a game changer in modern stroke management with addressable market ~\$5b**

**MICRO-X**



Above: Illustration of curved CT scanner in ambulance setting

# SIGNIFICANT MARKETS ACROSS FOUR PRODUCTION LINES

Sequenced Product Rollout as CNT Manufacturing Expands



Mobile DR Range

First Sales  
**2018**

Addressable Market

**US\$500m pa\***



IED X-Ray Camera

First Sales  
**2022\***

Addressable Market

**US\$1.8b**



Airport Checkpoint

First Sales  
**2023\***

Addressable Market

**USA: US\$8b**  
**RoW: US\$16b**



Brain CT Scanner

First Sales  
**2026\***

Addressable Market

**US\$5b**

\* Pre COVID-19 levels

\* These dates are estimates and may vary

# ESTABLISHED CAPABILITIES

Key Disciplines – Engineering Design, Development and Manufacturing

MICRO-X





# MILESTONES & ACHIEVEMENTS

Initiatives to Deliver Commercial Outcomes for all Stakeholders

MICRO-X

CY 2021

First IED X-Ray Camera Demonstration

Grow Micro-X Rover Paths to Market – US, EMEA

In-sourced Generator Tested

Launch Rover Veterinary

Rover Mk II – Second Generation Launched

Airport Security Contracts Signed

Brain CT Scanner Contract Signed

BEYOND

IED X-Ray Camera Prototype

Increased Mobile DR Sales

Scaling X-Ray Tube Manufacturing

IED X-Ray Camera Commercialisation

Brain CT Scanner Prototype

Airport Security Scanner Prototype

Airport Security Portal Prototype

ACN 153 273 735 / ASX: MX1

# MICRO-X

THANK YOU

Peter Rowland  
Managing Director & CEO



# EXPERIENCED LEADERSHIP

Technical and Commercial Expertise to Support Our Objectives

MICRO-X



**Peter Rowland**  
Managing Director & CEO

- Over 30 years' engineering and management in medical device & and aerospace industries
- Previously BAE Systems, Ellex Medical and Biolase Technology (NASDAQ)



**David Knox**  
Non-Executive Chairman

- Extensive international business experience delivering large energy projects
- Formerly CEO of Santos and Australian Naval Infrastructure
- Chair of Snowy Hydro, Director of CSIRO



**Patrick O'Brien**  
Non-Executive Director

- Over 25 years' business and finance experience in UK, Asia and Australia
- Former Executive Director at Macquarie Group; McKinsey; and Minter Ellison



**Yasmin King**  
Non-Executive Director

- Extensive experience in business, negotiation & procurement and Government
- Currently CEO of Skills IQ, formerly Associate Commissioner of ACCC
- Director of the Australian Healthcare and Hospitals Association



**Dr Alexander Gosling, AM**  
Non-Executive Director

- Over 40 years' business, technology and R&D experience
- A founding Director at Invetech (Vision Systems); strategy for Capstone



**Jim McDowell**  
Non-Executive Director

- Extensive experience in Defence and Aerospace industries
- Current CEO of Nova Group
- Former Chief Executive of the Department of Premier for South Australia




# CORPORATE SNAPSHOT

Growth Stage Company with Institutional Support



MX1 - Share Trading (1 September 2020 to 8 September 2021)



## Share & Trading Statistics (Closing Price on 8 September 2021)

Share Price	\$0.295 per share
Total Shares On Issue	459.7 million
Options Issued	2.5 million
Market Cap	~\$135.6m

## Key Financials & Shareholders

Cash	~\$30.1m (30 June 2021) – Debt free
Institutions	~40.0% Perennial (13.5%), Regal (8.9%), Thorney (5.7%), AusSuper (5.2%)
Board & Related Parties	~ 4.8%